Goldman Sachs
FLGT icon

Goldman Sachs’s Fulgent Genetics FLGT Stock Holding History

Goldman Sachs’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.95M Sell
311,423
-37,110
-11% -$805K ﹤0.01% 3700
2025
Q4 		$9.16M Buy
348,533
+164,535
+89% +$4.27M ﹤0.01% 3174
2025
Q3 		$4.16M Buy
183,998
+67,464
+58% +$1.39M ﹤0.01% 3816
2025
Q2 		$2.32M Sell
116,534
-86,286
-43% -$1.68M ﹤0.01% 4062
2025
Q1 		$3.43M Buy
202,820
+45,279
+29% +$771K ﹤0.01% 3715
2024
Q4 		$2.91M Buy
157,541
+29,818
+23% +$582K ﹤0.01% 3977
2024
Q3 		$2.78M Buy
127,723
+28,746
+29% +$643K ﹤0.01% 3851
2024
Q2 		$1.94M Buy
98,977
+15,207
+18% +$317K ﹤0.01% 3949
2024
Q1 		$1.82M Sell
83,770
-18,642
-18% -$463K ﹤0.01% 3932
2023
Q4 		$2.96M Sell
102,412
-1,290
-1% -$34.5K ﹤0.01% 3608
2023
Q3 		$2.77M Sell
103,702
-28,113
-21% -$960K ﹤0.01% 3503
2023
Q2 		$4.88M Buy
131,815
+60,820
+86% +$2.12M ﹤0.01% 3130
2023
Q1 		$2.22M Buy
70,995
+20,530
+41% +$661K ﹤0.01% 3779
2022
Q4 		$1.5M Sell
50,465
-25,097
-33% -$898K ﹤0.01% 4145
2022
Q3 		$2.88M Buy
75,562
+34,157
+82% +$1.71M ﹤0.01% 3637
2022
Q2 		$2.26M Sell
41,405
-76,132
-65% -$4.18M ﹤0.01% 3939
2022
Q1 		$7.34M Buy
117,537
+83,678
+247% +$5.51M ﹤0.01% 2994
2021
Q4 		$3.4M Sell
33,859
-400
-1% -$35.2K ﹤0.01% 3777
2021
Q3 		$3.08M Buy
34,259
+11,663
+52% +$1.06M ﹤0.01% 3794
2021
Q2 		$2.08M Buy
22,596
+5,441
+32% +$434K ﹤0.01% 4164
2021
Q1 		$1.66M Buy
17,155
+5,074
+42% +$524K ﹤0.01% 4167
2020
Q4 		$630K Buy
12,081
+1,927
+19% +$80.5K ﹤0.01% 4476
2020
Q3 		$407K Buy
+10,154
New +$318K ﹤0.01% 4593
2020
Q2 		– Sell
-31,131
Closed -$335K – 5293
2020
Q1 		$335K Buy
+31,131
New +$434K ﹤0.01% 4438
2017
Q1 		– Sell
-14,167
Closed -$164K – 6842
2016
Q4 		$164K Sell
14,167
-6,833
-33% -$64.5K ﹤0.01% 5903
2016
Q3 		$194K Buy
+21,000
New +$193K ﹤0.01% 5850

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's FLGT Position: Q1 2026 in Review

Goldman Sachs reduced its Fulgent Genetics (FLGT) stake by 11% in Q1 2026, selling an estimated $805K and leaving 311,423 shares worth $4.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3700.

Goldman Sachs first reported a position in FLGT in Q3 2016 and has held it in 26 quarters since. The position peaked at $9.16M in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Goldman Sachs held 311,423 shares of Fulgent Genetics worth $4.95M as of Q1 2026.
  • Goldman Sachs sold 37,110 Fulgent Genetics shares in Q1 2026, an estimated $805K.
  • Fulgent Genetics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3700 holding.
  • Goldman Sachs first reported a position in Fulgent Genetics in Q3 2016 and has held it in 26 quarters since.
  • Goldman Sachs's Fulgent Genetics position peaked at $9.16M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.